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Abstract
Understanding the links between genetic, epigenetic and non-genetic factors throughout the lifespan and across
generations and their role in disease susceptibility and disease progression offer entirely new avenues and solutions
to major problems in our society. To overcome the numerous challenges, we have come up with nine major
conclusions to set the vision for future policies and research agendas at the European level.
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The Human Genome Project was completed in 2003
and led to the identification of all human genes. How-
ever, the fundamental question that remains unanswered
is how do genes function and how are they regulated?
Epigenetics may provide many crucial answers. Epigene-
tics encompasses all processes that lead to heritable
changes in gene expression as cells divide, while epige-
nomics refers to analysis of epigenetic changes across
the whole genome in a cell or entire organism [1,2].
Typically, in a multi-cellular organism, each cell type will
be characterised by the same genome, along with as
many epigenomes as there are distinct cell types. Epigen-
etics combined with genetics is a rapidly growing field
with promising implications for health and disease be-
cause many common diseases result from the interplay
between the genetic make-up of individuals and the
environmental factors to which they are exposed [3].
Currently, however, there is limited knowledge on the
combined role of genetic and non-genetic factors thus
hampering personalised medicine. A conceptual goal is
to identify a cascade of genetic/epigenetic factors that
underlie the development of chronic diseases. For ex-
ample, a number of candidate genes have been associ-
ated with irritable bowel syndrome, but little research
has examined the mechanistic impact on epigenetics [4].
Likewise, even though environmental factors such as
stress, life-style, nutrition, air pollution and infections
lead to allergies, the genetic and epigenetic contributions
are not well understood [5,6].
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The reversible nature of epigenetic changes has attracted
interest in exploring their potential as targets for the
development of novel and more individualised medical
treatments.
Europe, with additional effort from Member States, is
showing leadership in the field of epigenetics and epige-
nomics and more than €200 Million were invested in re-
search projects and infrastructure through Framework
Programmes 6 and 7 (Table 1). For example, the BLUE-
PRINT project is focusing on distinct types of haemato-
poietic cells from healthy individuals and their malignant
leukaemic counterparts with the aim of generating at least
100 reference epigenomes and studying them to advance
and exploit knowledge of the underlying biological pro-
cesses and mechanisms in health and disease [7].
With this aim, the European Commission's Directorate
General for Research and Innovation (DG RTD) and
Cooperation in Science and Technology (COST) orga-
nised a joint strategic workshop “Relationship between
genome and epigenome”. The workshop addressed the
links between genetic, epigenetic and non-genetic factors
throughout the lifespan and across generations, their
role in health and disease including disease susceptibility
and progression, and the associated challenges of data
handling/storage and interpretation. The outcomes of
the workshop will inform future research priorities and
are summarised in Figure 1.
Major issues for future research include the following
points:
1) In order to identify good surrogate epigenomic
marks that would corroborate the influence of
environmental exposure on the epigenome
(including periconception environment, lifestyle,
reproductive factors, microbiome etc.) and allow for
the prediction and prevention of the development
of chronic diseases, detailed research in humans and
model organisms and careful sample acquisition
(more tissue and cell specific epigenomes, time
series, epigenomic variation etc.) is required.
Parental conditions before, during and after
conception (periconception period) may induce
epigenetic changes in gametes and embryos [8].
Such changes may adversely affect the offsprings’
future health, development, productivity and fertility
[3]. The connection between the perinatal factors
and later outcomes in life was illustrated by
describing the relationship between birth weight and
incidence of diseases in older age such as cardiac
disease [9]. Studies of historical famines already
yielded key evidence for the association of early life
environmental exposure and differences in the adult
epigenome [10]. Like the field itself, these studies are
in their infancy and ongoing genome-wide studies
are expected to result in the identification of epigenetic
alterations that are triggered by non-genetic factors
leading to particular disease phenotype. The microbiome
has strong parallels with the epigenome in that it is
complex and may reflect environmental exposure
(of the host from which the micobiome was obtained)
and might also impact on how non-genetic factors lead
to epigenetic changes (i.e. by modulating hormonal
levels [11]). Accumulating data demonstrate a crucial
impact of the microbiome on health and disease.
2) With the increase of chronological age, an increase
of gene promoter methylation paralleled by global
hypomethylation across the genome can be observed.
This is remarkably similar to the DNA methylation
changes seen in cancer [12] suggesting that similar
underlying mechanisms may be involved. More
age-stratified data are required to understand the
relationship between the epigenome, the microbiome
and the environment during the course of life and its
impact on allergy and chronic diseases.
3) The genome-epigenome interaction is also crucially
involved in the biology, character and extent of an
established disease and not just in disease development.
This is reflected for instance in the role that the
chromatin and epigenome plays in DNA damage repair
[13]. Epigenetic markers allow for the prediction of
the natural behaviour of a disease (prognostic markers)
and the likelihood of responding to a specific treatment
(predictive markers). Testing and validating these
markers in clinical trials and benchmarking against
established strategies will be crucial in order to
improve disease outcome.
4) Studies of the effects and the mechanistic impact
of epidrugs (drugs that can effect epigenomic
modifications) and their impact on the genome,
development and validation of new epigenetic drug
candidates and rational design of combination
therapies of genetic and epigenetic drugs should be
encouraged to cure diseases or at least improve the
efficacy of current treatment modalities as recently
demonstrated [14]. Structural and functional
information from chromatin and DNA modifying
enzymes and the development of small molecules
active on specific epi-targets are crucial for the
development of new therapeutic approaches.
Epigenetic therapy tries to reverse such aberrations
following disruption of the epigenetic signal balance
through the use of both natural compounds and
synthetic molecules [15]. For instance, pharmacological
inhibition of EZH2 (enhancer of zeste homolog 2, a
Histone-lysine N-methyltransferase) was recently
shown as a promising new tool with which to treat
cancer [16]. Many clinical trials are already ongoing,
and epigenetic therapy (azacytidine) has recently been
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Table 1 FP7 Cooperation projects and network of excellence that were represented at the workshop
Acronym Project description Website
ATLAS Development of Laser-Based Technologies and Prototype
Instruments for Genome-Wide Chromatin ImmunoPrecipitation
Analyses
http://www.atlas-eu.com/
BLUEPRINT A BLUEPRINT of haematopoietic Epigenomes http://www.blueprint-epigenome.eu/
CANCERDIP The use of Methylated DNA Immunoprecipitation MeDIP in
cancer for better clinical management
http://www.cancerdip.eu/
CELLOMATIC High Throughput Systematic Single Cell Genomics using
Micro/Nano-Fluidic Chips for Extracting, Pre-analysing,
Selecting and Preparing Sequence-ready DNA
http://www.cellomatic.eu/
CURELUNG Epigenetic therapeutic strategies for improving lung cancer
diagnosis
http://www.curelung.eu/
ELIXIR European Life-Science Infrastructure http://www.elixir-europe.org/about
EPIFEMCARE Epigenetics for Female Personalised Cancer Care http://www.epifemcare.eu/
EPIGENESYS Epigenetics towards systems biology http://www.epigenesys.eu/
ESGI European Sequencing and Genotyping Infrastructure http://www.esgi-infrastructure.eu/
EUROBATS Identifying biomarkers of ageing using whole transcriptome
sequencing
http://www.eurobats.eu/
GENCODYS Genetic and Epigenetic Networks in Cognitive Dysfunction http://www.gencodys.eu/index.php
GENICA Genomic instability in cancer and pre-cancer http://genica.unige.ch/
GEUVADIS Genetic European Variation in Disease http://www.geuvadis.org/
IDEAL Integrated research on developmental determinants of Aging
and Longevity
http://www.ideal-ageing.eu/
MARK-AGE European study to establish biomarkers for human aging http://www.mark-age.eu/
MEDALL Mechanisms of the Development of ALLergy http://medall-fp7.eu/
MODHEP An integrative genomic-epigenomic approach to liver cancer http://www.modhep.eu/
NGS-PTL Next Generation Sequencing platform for targeted Personalized
Therapy of Leukemia
http://www.ngs-ptl.com/
RADIANT Rapid development and distribution of statistical tools for
high-throughput sequencing data
http://www.radiant-project.eu/
READNA REvolutionary Approaches and Devices for Nucleic Acid Analysis http://www.cng.fr/READNA/
SETTREND Schistosoma epigenetics: targets, regulation, new drugs http://settrend.cebio.org/
SIROCCO Silencing RNAs: organisers and coordinators of complexity in
eukaryotic organisms
http://www.sirocco-project.eu/
SWITCHBOX Homeostatic mechanisms to facilitate maintenance of health
from early life through to aging
http://www.switchbox-online.eu/
International consortia
IHEC International Human Epigenome Consortium http://www.ihec-epigenomes.org/
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Table 1 FP7 Cooperation projects and network of excellence that were represented at the workshop (Continued)
Cost actions
TD0905 Epigenetics from bench to bedside http://www.cost.eu/domains_actions/cmst/Actions/TD0905
COST- FA1201– Epigenetics and periconception environment http://www.cost.eu/domains_actions/fa/Actions/FA1201
COST-BM– 1201 Developmental origins of chronic lung diseases http://www.cost.eu/domains_actions/bmbs/Actions/BM1201
COST- BM1102 Ciliates as model systems to study genome
evolution, mechanisms of non-Mendelian inheritance, and their
roles in environmental adaptation
http://www.cost.eu/domains_actions/bmbs/Actions/BM1102
COST Action BM1106 ‘The Genes in Irritable Bowel Syndrome
Research Network Europe (GENIEUR)’
http://www.cost.eu/domains_actions/bmbs/Actions/BM1106
COST-BM1007 – Mast cells and basophils – targets for innovative
therapies
http://www.cost.eu/domains_actions/bmbs/Actions/BM1007
BM1006 Next Generation Sequencing Data Analysis network
(SeqAhead)
http://www.cost.eu/domains_actions/bmbs/Actions/BM1006
BM0806 - Recent advances in histamine receptor H4R research http://www.cost.eu/domains_actions/bmbs/Actions/BM0806
BM0801 Translating Genomic and epigenetic Studies of MDS and
AML (EUGESMA)
http://www.cost.eu/domains_actions/bmbs/Actions/BM0801
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approved by the United States Food and Drug
Administration (US FDA) for use in the treatment
of Myelodysplastic Syndrome (MDS) and Primary
Cutaneous T-cell Lymphoma (CTCL) [17].
5) Studies to identify functional relationships between
epigenetics and genetics require analysis of ex vivo
samples of primary cells, and therefore the sampling,
sorting and analytical procedures need to be
optimised and adapted. Cell heterogeneity (variation
among cells) is a challenge in gaining a thorough
understanding of genome status, gene expression
and the role of underlying epigenetic mechanisms.
This is true for many cellular processes, such as
genome remodeling during reprogramming or the
conversion of somatic cells to pluripotent cells.
Therefore collecting the most appropriate samples
in order to address a specific set of questions and
miniaturization of technologies for the analyses of
single cells [18,19] is crucial.
6) Epigenomic and genomic data sets are complex and
multi-dimensional, and their interpretation requires
the further development of data analysis tools/soft-
ware. A large amount of data has already been
acquired and is highly multidimensional and multi-
modal; therefore it is the analysis that remains the
challenge. DNA and chromatin exist in a 3D space.
Transcriptome data are complex: all transcripts,
including non-coding (nc) RNAs, overlap other
transcripts and quantification is not trivial. Performing
data analysis by integrating data from different
repositories (some of which are difficult to find) is
problematic because of the different methodologies
used to acquire the data sets [20]. There is a need
to establish robust benchmarks for data analysis for
the comparison of different analytical approaches/
software.
7) Integrating the findings from -omics research into
clinical practice is one of the major challenges of the
future. Systems biology approaches are advantageous
in providing predictive models of associations
between epigenomic/genomic data and phenotypes
offering an entry point for assays into functional
relationships. Understanding the functional/mechanistic
role of epigenetic marks is highly desirable, but that
in many cases it may be difficult to directly obtain
such insight. Systems biological approaches could
identify predictive models from multi-modal data
to support associations that can then be tested in
functional models.
8) Improved collaborations should be fostered by
the establishment and harmonization of standard
operating procedures for sample processing, data
acquisition and formatting; and by the development of
software that is user-friendly for the non-specialist as
well as facilitating an Open Access policy to allow free
data sharing and automatic mining of publications.
Current European effort should be aligned with those
of the International Human Epigenome Consortium
(http://www.ihec-epigenomes.org/) coordinating
epigenome mapping and characterisation worldwide
to avoid redundant research effort, to implement
high data quality standards, to coordinate data storage,
management and analysis and to provide free access
to the epigenomes produced.
Figure 1 Understanding the relationship between genome and epigenome and their role in health and disease enables the
development of tools for personalized medicine including risk prediction, disease prevention and treatment. The EU funding provides a
platform, enables collaborative work and facilitates to achieve the set aims in order to consolidate Europe's leadership position in Epigenetics.
Almouzni et al. BMC Genomics 2014, 15:487 Page 5 of 7
http://www.biomedcentral.com/1471-2164/15/487
9) European Union (EU) consortia and COST Actions
have tremendously shaped and consolidated Europe’s
leadership position in Epigenetics and can provide
indispensable means for young researchers to
become principal investigators and future European
leaders by integrating them into networks of
experienced scientists/clinicians. EC funding
schemes should devote further effort to principal
investigators career development.
The European Union is currently funding over 300
epigenetics projects (a High Impact Project, Collaborative
Projects, Networks of Excellence, ERC (European
Research Council) Starting Grants, ERC Advanced Grants,
Marie Curie Actions) with a total contribution of more
than €200 Million.
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